OBX-115 Engineered TIL Cell Therapy with Regulatable Membrane-Bound IL15: Initial Multicenter Clinical Trial Results in Advanced Melanoma

Time: 8:30 am
day: Conference Day One AM

Details:

• OBX-115 TIL is engineered to express membrane-bound IL15 regulated by acetazolamide, abrogating the need for IL2
• OBX-115 is compatible with low-dose lymphodepletion and has a positively differentiated safety profile
• At RP2D, OBX-115 can induce deep and durable responses in patients with ICIresistant advanced melanoma

Speakers:

Madan Jagasia Madan Jagasia, M.D., M.S., is Obsidian’s Chief Executive Officer. Dr. Jagasia is a highly experienced physician executive with an extensive oncology and cell therapy-focused clinical Read more